Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.
STAT+: Eli Lilly’s obesity pill helped patients maintain weight loss after switch from injections
Eli Lilly’s investigational obesity pill largely helped patients maintain their weight loss after they switched from the potent injectable treatments Wegovy and Zepbound, the company said Thursday, results that could widen the appeal of the pill. In a Phase 3 trial, one cohort of patients had an average starting weight of 113.5 kg. After over […]
STAT+: Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow
When HCA Healthcare, one of the largest hospital systems in the U.S., recently told employees it would stop covering blockbuster obesity drugs Zepbound and Wegovy next year, it pointed them to an alternative way to get the treatments: Buy them themselves. In a notice viewed by STAT, HCA said use of the GLP-1 weight loss […]
Beyond Weight Loss: GLP-1s Show Promise in Breast Cancer
A growing body of evidence suggests GLP-1 receptor agonists may improve survival as well as reduce chemotherapy-related toxicities in women with breast cancer. Medscape Medical News
IJMS, Vol. 26, Pages 12163: GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
IJMS, Vol. 26, Pages 12163: GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review International Journal of Molecular Sciences doi: 10.3390/ijms262412163 Authors: María Paz Orozco Valentina Vintimilla Rivadeneira Jose E. Leon-Rojas Parkinson’s disease (PD) is a complex neurodegenerative disorder characterised by progressive motor and non-motor impairment, in which current therapies remain symptomatic […]
Recent articles on GLP-1 receptor agonists have presented as part of secondary analyses an effect,trial-product estimand, that may be unfamiliar.
submitted by /u/Accurate_Cry_8937 [link] [comments]
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
SAN FRANCISCO and SUZHOU, China, Dec. 17, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and…
Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics
(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, a large…
Weight Watchers Launches New GLP-1 Program and AI App Features
What You Should Know: – Weight Watchers has unveiled a massive platform overhaul integrating GLP-1 prescription management with a redesigned app featuring an AI body scanner and a “Weight Health Score.” – The new “Med+” and “GLP-1 Success” programs offer specialized support for medication users, including nutrition plans to preserve muscle mass and direct access […]
Is cost curbing use of weight loss drugs?
Anna Sinaiko. Stephanie Mitchell/Harvard Staff Photographer Health Is cost curbing use of weight loss drugs? 40 percent of GLP-1 prescriptions go unfilled, study finds Alvin Powell Harvard Staff Writer December 17, 2025 4 min read Popular new anti-obesity medications can help people lose 10 to 20 percent of their body weight, yet a new study […]